Comparative Pharmacology
Head-to-head clinical analysis: MELLARIL versus NAVANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELLARIL versus NAVANE.
MELLARIL vs NAVANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors, and also blocks alpha-adrenergic receptors, histamine H1 receptors, and muscarinic M1 receptors.
Thioxanthene neuroleptic; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic blocking, and sedative effects.
Typical adult dose: 10-25 mg orally 3 times daily. Maximum dose: 200 mg/day.
Oral: 10-20 mg three times daily; maximum 160 mg/day. IM (acute): 5-10 mg every 4-6 hours; maximum 30 mg/day.
None Documented
None Documented
Terminal elimination half-life 21-24 hours; steady-state achieved within 5-7 days
Terminal elimination half-life is approximately 20-24 hours, allowing for once-daily dosing. Steady-state reached in 4-5 days.
Primarily renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Primarily hepatic metabolism; approximately 20-30% excreted renally as metabolites, <1% unchanged. Biliary/fecal excretion accounts for ~50% of metabolites.
Category C
Category C
Antipsychotic
Antipsychotic, Typical